Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide
Authors:
Open Access
- 1 January 2022
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 15
Abstract
Women with epilepsy (WWE) wishing for a child represent a highly relevant subgroup of epilepsy patients. The treating epileptologist needs to delineate the epilepsy syndrome and choose the appropriate anti-seizure medication (ASM) considering the main goal of seizure freedom, teratogenic risks, changes in drug metabolism during pregnancy and postpartum, demanding for up-titration during and down-titration after pregnancy. Folic acid or vitamin K supplements and breastfeeding are also discussed in this review. Lamotrigine and levetiracetam have the lowest teratogenic potential. Data on teratogenic risks are also favorable for oxcarbazepine, whereas topiramate tends to have an unfavorable profile. Valproate needs special emphasis. It is most effective in generalized seizures but should be avoided whenever possible due to its teratogenic effects and the negative impact on neuropsychological development of in utero-exposed children. Valproate still has its justification in patients not achieving seizure freedom with other ASMs or if a woman decides to or cannot become pregnant for any reason. When valproate is the most appropriate treatment option, the patient and caregiver must be fully informed of the risks associated with its use during pregnancies. Folate supplementation is recommended to reduce the risk of major congenital malformations. However, there is insufficient information to address the optimal dose and it is unclear whether higher doses offer greater protection. There is currently no general recommendation for a peripartum vitamin K prophylaxis. During pregnancy most ASMs (e.g. lamotrigine, oxcarbazepine, and levetiracetam) need to be increased to compensate for the decline in serum levels; exceptions are valproate and carbamazepine. Postpartum, baseline levels are reached relatively fast, and down-titration is performed empirically. Many ASMs in monotherapy are (moderately) safe for breastfeeding and women should be encouraged to do so. This review provides a practically oriented overview of the complex management of WWE before, during, and after pregnancy.Keywords
This publication has 236 references indexed in Scilit:
- Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood AutismJAMA, 2013
- High dose folic acid supplementation of rats alters synaptic transmission and seizure susceptibility in offspringScientific Reports, 2013
- Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational studyThe Lancet Neurology, 2013
- Folic Acid Transport to the Human Fetus Is Decreased in Pregnancies with Chronic Alcohol ExposurePLOS ONE, 2012
- Folic acid to reduce neonatal mortality from neural tube disordersInternational Journal of Epidemiology, 2010
- Valproic acid in pregnancy: How much are we endangering the embryo and fetus?Reproductive Toxicology, 2009
- Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic DrugsNew England Journal of Medicine, 2009
- Antiepileptic Drug-Induced Neuronal Cell Death in the Immature Brain: Effects of Carbamazepine, Topiramate, and Levetiracetam as Monotherapy versus PolytherapyThe Journal of Pharmacology and Experimental Therapeutics, 2007
- The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialThe Lancet, 2007